Lupin Receives US FDA Tentative Approval For Apixaban Oral Suspension 1.25mg/mL
Mumbai: Lupin Limited on Monday, September 28, 2026, announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its New Drug Application (NDA) for Apixaban Oral Suspension 1.25mg/mL. Product Details Lupin’s Apixaban Oral Suspension 1.25mg/mL is an oral liquid formulation of apixaban, the active ingredient also found in Eliquis, a product…
We haven't written up this one. Free Press Journal has the full story — the link below goes straight to it.
